why choose us

Clinical Trials Search

Showing 10,670 of 132,656 result(s)
TMS + Exposure Therapy for Pediatric OCD

Status: NOT_YET_RECRUITING

Condition: Obsessive-Compulsive Disorder

Interventions: TMS will be delivered over the dorsolateral prefrontal cortex (dlPFC) using an intermittent bursting pattern

Date: 2023-06-15

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Status: Completed

Condition: Single Ventricle Heart Disease

Interventions: Active drug

Date: 2023-06-15

Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19

Status: Completed

Condition: COVID-19

Interventions: Capsule administered orally after meals.

Date: 2023-06-15

Emotional Changes Between Emergency and Intensive Care Unit and On-site Counter Staffs After COVID-19 Infection

Status: Completed

Condition: Psychological Distress

Interventions: Emotional Changes between Emergency and Intensive care unit and On-site Counter Staffs after COVID-19 Infection and Exploring The Impact of Personnel

Date: 2023-06-15

Prediction of Conversion From Vv-ECMO to Va-ECMO in COVID-19 Patients

Status: NOT_YET_RECRUITING

Condition: ARDS Due to Disease Caused by SARS Co-V-2

Interventions: Conversion from vv-ECMO to va-ECMO

Date: 2023-06-15

Have Physical Therapists Attitudes and Beliefs Towards Vital Assessment Changed Following the COVID-19 Pandemic?

Status: NOT_YET_RECRUITING

Condition: Vital Signs

Interventions: This is a cross-sectional study that utilizes a KAP (knowledge, attitude, and practice) survey.
This type of survey can be conducted on a represe

Date: 2023-06-15

Daratumumab for Relapsed;Refractory Primary Effusion Lymphoma

Status: NOT_YET_RECRUITING

Condition: Lymphoma, Primary Effusion

Interventions: Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg;30,000 units weekly for a total of 8 weeks (8 doses

Date: 2023-06-15

Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency

Status: NOT_YET_RECRUITING

Condition: GATA2

Interventions: 15 mg;kg IV three times per day starting on day +5 until approximately day +30 (+;- 2 days)

Date: 2023-06-15

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Status: NOT_YET_RECRUITING

Condition: Anatomic Stage I Breast Cancer

Interventions: Undergo endocrine therapy

Date: 2023-06-15